• 1. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 2. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 3. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 4. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 5. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acid esters
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Benzoic acid esters

Methyl 2-amino-3-iodobenzoate (CAS No. 180161-60-8): A Key Intermediate in Modern Pharmaceutical Synthesis

Methyl 2-amino-3-iodobenzoate (CAS No. 180161-60-8) is a specialized organic compound that has garnered significant attention in the field of pharmaceutical synthesis and medicinal chemistry. This compound, characterized by its unique structural features, serves as a crucial intermediate in the development of various therapeutic agents. Its molecular structure, incorporating both amino and iodine substituents, makes it particularly valuable for constructing complex pharmacophores essential for drug design.

The Methyl 2-amino-3-iodobenzoate molecule consists of a benzoate backbone with an amino group at the 2-position and an iodine atom at the 3-position. This arrangement provides a versatile platform for further chemical modifications, enabling the synthesis of a wide array of derivatives with tailored biological activities. The presence of the amino group allows for nucleophilic substitution reactions, while the iodine atom facilitates cross-coupling reactions such as Suzuki-Miyaura and Stille couplings, which are pivotal in constructing biaryl structures prevalent in many modern drugs.

In recent years, there has been a surge in research focused on developing novel therapeutic agents targeting various diseases, including cancer, infectious diseases, and inflammatory disorders. The demand for innovative drug candidates has driven the exploration of diverse chemical scaffolds, and compounds like Methyl 2-amino-3-iodobenzoate have emerged as indispensable tools in this endeavor. The compound's ability to undergo multiple functionalization steps makes it an excellent starting point for generating libraries of compounds for high-throughput screening.

One of the most compelling applications of Methyl 2-amino-3-iodobenzoate is in the synthesis of kinase inhibitors, which are widely used in cancer therapy. Kinases play a critical role in cell signaling pathways, and their dysregulation is often associated with tumor growth and progression. By leveraging the compound's reactive sites, researchers can design molecules that selectively inhibit specific kinases, thereby disrupting abnormal signaling networks. For instance, derivatives of Methyl 2-amino-3-iodobenzoate have been explored as inhibitors of tyrosine kinases, showing promise in preclinical studies.

The role of Methyl 2-amino-3-iodobenzoate extends beyond kinase inhibition; it has also been utilized in the development of antimicrobial agents. The increasing prevalence of antibiotic-resistant bacteria has necessitated the discovery of novel antimicrobial compounds. The structural features of Methyl 2-amino-3-iodobenzoate, particularly its ability to interact with bacterial enzymes and cell wall components, make it a valuable building block for designing new antibiotics. Recent studies have demonstrated its incorporation into molecules that exhibit potent activity against Gram-positive and Gram-negative bacteria.

In addition to its applications in oncology and antimicrobial therapy, Methyl 2-amino-3-iodobenzoate has found utility in addressing inflammatory diseases. Chronic inflammation is a hallmark of many pathological conditions, including autoimmune disorders and cardiovascular diseases. Researchers have harnessed the compound's reactivity to develop inhibitors of inflammatory pathways. For example, derivatives derived from Methyl 2-amino-3-iodobenzoate have been investigated as modulators of cyclooxygenase (COX) enzymes, which are key players in the production of pro-inflammatory mediators.

The synthetic methodologies employed in the preparation of Methyl 2-amino-3-iodobenzoate are also worth mentioning. The compound is typically synthesized through multi-step organic transformations that involve halogenation and functional group interconversion. Advanced techniques such as palladium-catalyzed cross-coupling reactions have been employed to introduce the iodine atom at the 3-position with high precision. These synthetic strategies not only highlight the versatility of Methyl 2-amino-3-iodobenzoate but also showcase the ingenuity of modern synthetic organic chemistry.

The industrial significance of Methyl 2-amino-3-iodobenzoate cannot be overstated. Its role as a key intermediate has positioned it as a cornerstone material in pharmaceutical manufacturing. The demand for high-purity compounds like this one underscores the importance of robust synthetic routes that ensure scalability without compromising quality. As pharmaceutical companies continue to expand their pipelines of novel drugs, compounds like Methyl 2-amino-3-iodobenzoate will remain indispensable in their quest for innovative therapeutics.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)